Provention Bio Inc. (PRVB) PT Raised to $20 at H.C. Wainwright
Get Alerts PRVB Hot Sheet
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Provention Bio Inc. (NASDAQ: PRVB) to $20.00 (from $8.00) while maintaining a Buy rating. Earlier this month, Provention Bio reported that a Phase 2 clinical trial the Teplizumab for Prevention of Type 1 Diabetes In Relatives “At-Risk” trial had yielded highly favorable results.
Selvaraju believes that the data from the company's at-risk trial is clearly meaningful enough to warrant a potential acceleration of teplizumab's progression to market entry. H.C. Wainwright revised assumptions involve the scenario that teplizumab could be filed with the FDA later this year or early next year; this could lead to market entry in 2021.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- BofA Securities Upgrades Estee Lauder (EL) to Buy; 'Earnings have bottomed'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
H.C. Wainwright, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!